Melanotan II
Pharmaceutical name: Melanotan II
Pack: 1 vial/10mg
Melanotan II was developed originally as potential preventative treatments for various forms of skin cancer. It was thought that by artificially stimulating the internal tanning process among members of the population that were at high risk to develop skin cancer due to sun exposure that one may be able to lower the chances of these individuals from developing the disease later in life. Along with the benefits of providing a tan without the need for extensive exposure to sunlight as well as improved sexual performance and/or desire, Melanotan II also may help to decrease the appetite via targeting an appetite-suppression receptor in the brain. This effect is not an overwhelming one but is noticeable for the majority of users and desirable for many. The duration of the tanning effect of the drug once a user ceases administering it will once again depend on several factors. The majority of users however will notice that the tan achieved with the drug will fade and become unnoticeable within four to eight weeks after ceasing the administration of the drug. For most individuals, during the loading phase with the hormone, a range of between 0.015 to 0.02 milligrams per kilogram of body weight per injection should be sufficient. These injections would take place anywhere from twice daily to as infrequently as once every other day or longer. For the maintenance phase many individuals will find that a dose of approximately 0.01 milligrams per kilogram of body weight administered once every few days should be sufficient to maintain the effects of the hormone.

Melanotan 2 (CAS NO. 121062-08-6) was first synthesized at the University of Arizona. Researchers decided to find a more potent and stable alternative, one that would be more practical to defenses against skin cancer. It was under development as drug candidate for female sex dysfunction and erectile dysfunction,
Melanotan 2I acts as a non-selective agonist of the melanocortin receptors. The melanogenesis produced by melanotan 2 is caused by activation of the MC1 receptor, whereas its sex effects are thought to be related to its ability to activate the MC4 receptor (though the MC3 is thought to possibly also be involved). Melanotan II is a peptide hormone belonging to the alpha-melanocyte-stimulating hormone (alpha-MSH) class of mimetics. Melanotan II is a synthetic analog pituitary derived Melanocortin. The peptide is primarily known for its ability to help with tanning but is also used to aid in erectile function. Melanotan II, also referred to as MT-2, has no use of significance beyond tanning and erectile function.

Melanotan II (also known as MT-II or MT-2) is an injectable peptide hormone used to promote tanning. MT-II works by stimulating alpha-melanocyte receptors, which promotes formation of melanin in response to sun exposure. When a substantial amount of MT-II has been taken within recent "memory" of the skin cells, an individual tans as if he were a genetically darker type.

Melanotan II analog of alpha-melanocyte stimulating hormone (a-MSH). Melanotan peptides are safe and efficacious with growing long term data. Melanotan 2 is a freeze dried peptide sealed in a sterile multi-use vial. Tanning injections of synthetic potent a-MSH allow for development of photo-protective suntans in all skin types.

Appearance: Powder

Purity: >99% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Semaglutide is a new generation GLP-1 (glucagon-like peptide-1) analogues. Semaglutide is a long-acting dosage form based on the basic structure of liraglutide, which is more effective in the treatment of type 2 diabetes mellitus. Compared with lilarlutide, somalutide has a longer aliphobic chain and an increased hydrophobicity, but somalutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced.PEG modification can not only tightly bind to albumin, cover up the DPP-4 enzymatic hydrolysis site, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation.

Molecular Weight: 4813.45

Appearance: White Powder

Purity (HPLC): ≥99.0%

Single Impurity (HPLC): ≤1.0%

Moisture Content (Karl Fischer): ≤10.0%

Peptide Content: ≥80.0%

Storage: Store at -20℃ degrees Celsius in a dry and cool place.